Overview

Full Product Details

Author:   Ronald M. Bukowski ,  Robert A. Figlin ,  Robert J. Motzer
Publisher:   Springer-Verlag New York Inc.
Imprint:   Springer-Verlag New York Inc.
Edition:   Softcover reprint of the original 3rd ed. 2015
Dimensions:   Width: 15.50cm , Height: 3.20cm , Length: 23.50cm
Weight:   9.416kg
ISBN:  

9781493950638

ISBN 10:   1493950630
Pages:   613
Publication Date:   23 August 2016
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Paperback
Publisher's Status:   Active
Availability:   Manufactured on demand  
We will order this item for you from a manufactured on demand supplier.

Table of Contents

Ch. 1: Targeted Therapy for Metastatic Renal Cell Carcinoma : the First Ten Years; Ch. 2: RCC: Pathologic and Molecular assessment of Targets; Ch. 3: Targeted Therapy for Metastatic Renal Cell Carcinoma : the First Ten Years; Ch. 4: VHL and HIF in clear cell Renal Cell Carcinoma: Molecular Abnormalities and Potential Clinical Applications; Ch. 5: PBRM1: A Critical Subunit of the SWI/SNF Chromatin Remodeling Complex; Ch. 6: Sporadic RCC – Abnormalities in Histone Modifying Genes; 7: Genetic Heterogeneity in Renal Cell Carcinoma: Clinical Implications?; Ch. 8: First-Generation Tyrosine Kinase Inhibitors – Clinical Results;  9: Second Generation Tyrosine Kinase Inhibitors (Pazopanib) in Renal Cell Carcinoma: Current Status; Ch. 10: Third Generation TKIs (Axitinib, Tivozanib) in RCC: enhanced efficacy and diminished toxicity?; Ch. 11: Anti-VEGF and VEGFR monoclonal antibodies in RCC; Ch. 12: PI3-Kinase, Akt, and mTOR Inhibitors in RCC; Ch. 13: Carbonic anhydrase IX & Monoclonal Antibody G250: relevance as a clinical and biologic target in Renal Cell Carcinoma; Ch. 14: EGFR and HER2: Relevance in Renal Cell Carcinoma; Ch. 15: The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma; Ch. 16: Development of Resistance to Targeted Therapy: Preclinical Findings and Clinical Relevance; Ch. 17: Development of Combination Therapy with Targeted Agents; Ch. 18: Side Effects ofTargeted Thearpy; Ch. 19: The Role of Targeted Therapy in Special Populations; Ch. 20: Immunotherapy: the Current Role of Cytokines; Ch. 21: Immune Checkpoint Inhibitors (anti-CTLA4, anti PD-1) in RCC; Ch. 22: Vaccines in RCC: Clinical and Biological Relevance; Ch. 23: Development and Incorporation of Biomarkers in RCC Therapeutics; Ch. 24: Molecularly Targeted Staging Strategies in Renal Cell Carcinoma; Ch. 25: Clinical Prognostic Factors in Metastatic Renal Cell Carcinoma; Ch. 26: The Role of Advocacy in Renal Cell Carcinoma

Reviews

From the book reviews: This is an important reference for practicing medical oncologists, urologists, and researchers interested in the biology and therapy of this disease. ... This book details the most recent research into the molecular targets of RCC and applications for clinical drug development. ... It should be part of libraries for clinicians or basic scientists dealing with RCC. It certainly is an excellent reference for basic and translational scientists and clinicians in this field. (Jianqing Lin, Doody's Book Reviews, February, 2015)

From the book reviews: This is an important reference for practicing medical oncologists, urologists, and researchers interested in the biology and therapy of this disease. ... This book details the most recent research into the molecular targets of RCC and applications for clinical drug development. ... It should be part of libraries for clinicians or basic scientists dealing with RCC. It certainly is an excellent reference for basic and translational scientists and clinicians in this field. (Jianqing Lin, Doody's Book Reviews, February, 2015)

Author Information

Ronald M Bukowski MD Emeritus Staff Physician Cleveland Clinic Taussig Cancer Center Professor Emeritus of Medicine CCF Lerner College of Medicine of CWRU Robert Figlin MD Professor of Medicine and Biomedical Sciences Director, Division of Hematology Oncology Department of Medicine, Cedars-Sinai Medical Center Associate Director for Academic Programs Samuel Oschin Comprehensive Cancer Institute Professor Emeritus of Medicine and Urology David Geffen School of Medicine at UCLA Robert Motzer MD Attending Physician Department of Medicine Memorial Sloan-Kettering Cancer Center Professor of Medicine Weil Medical College of Cornell University

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions